If you’re working on Dry Powder Inhaler (DPI) formulations, you already know the challenge: drug retention. Active powder trapped inside the capsule means less medication reaches the patient — and in respiratory care, even a fraction of a milligram makes a difference.

At CPHI China 2026, we’re excited to showcase EMBOCAPS® LPR (Low Powder Retention) — our capsule solution engineered specifically for pulmonary drug delivery, designed to ensure that medication goes exactly where it belongs: deep into the patient’s lungs.

Why formulation teams trust EMBOCAPS® LPR:

📉 Minimal Powder Retention — Advanced surface engineering minimises static charge and powder adhesion, maximising dose delivery

🎯 Fragment-Free Puncturing — Optimised shell brittleness guarantees clean, consistent puncturing for patient safety

💧 Strict Moisture Control — Tailored moisture specifications protect even the most hygroscopic powders throughout shelf life

Whether you’re in early-stage R&D or scaling up production, our team is ready to discuss how EMBOCAPS® LPR can address your specific inhalation drug delivery challenges.

Come meet our experts at CPHI China 2026:

🗓 Date: June 16–18, 2026

📍 Location: Shanghai, SNIEC

🎪 Booth: E3C32

We look forward to seeing you in Shanghai.